Research Explained in 70 Seconds – UMB on Instagram Feb. 15th, 2023 Imagine being able to carry artificial blood to a wounded soldier in a remote area to save their life. That’s one of the potential benefits of a $46.4 million study to develop and test artificial...
Baltimore’s KaloCyte Partners on $46M DARPA Program to Develop Synthetic Blood Product Feb. 6, 2023 “This partnership with DARPA is highly complementary to our work,” Elaine Haynes, President and Chief Executive Officer of KaloCyte said. DARPA will provide $46...
The Pittsburgh Post-Gazette: DARPA Puts $46.4M Toward Synthetic Blood Development Feb. 3, 2023 The Defense Advanced Research Projects Agency announced it will grant a total of $46.4 million to a number of organizations, including KaloCyte, UMB, and the University of...
ErythroMer Featured in Drug Discovery News – December 2022/January 2023 Issue Nov. 17th, 2022 Facing donor shortages and storage limitations, researchers are developing synthetic red blood cells, platelets, and plasma and combining them into artificial blood. Read...
DARPA Team Begins Work on Field Deployable Whole Blood Equivalent Jan. 31, 2023 KaloCyte to participate in DARPA’s Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products (FSHARP) program, to develop a field-deployable, shelf-stable whole blood...
David J. Ramsay Entrepreneur of the Year Video Presentation Nov. 17th, 2022 The University of Maryland, Baltimore (UMB) produced this video showcasing the work of KaloCyte Co-Founder and Chief Scientific Officer, Allan Doctor MD; recipient of the 2022 David J....
